Clinical applications of intravenous immunoglobulins in neurology

Clinical and Experimental Immunology

Volumn 158, Issue SUPPL. 1, 2009, Pages 34-42

  Hughes, R A C ^b,c   Dalakas, M C ^d   Cornblath, D R ^a   Latov, N ^a   Weksler, M E ^d   Relkin, N ^d  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Alzheimer's disease; Autoimmune myopathy; Chronic inflammatory demyelinating polyradiculoneuropathy; Guillain Barr syndrome; Intravenous immunoglobulin

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN[1-40]; BETA INTERFERON; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; PLACEBO; PREDNISONE; STEROID;

ALZHEIMER DISEASE; CEREBROSPINAL FLUID; CLINICAL TRIAL; COGNITION; DERMATOMYOSITIS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNOTHERAPY; INCIDENCE; INCLUSION BODY MYOSITIS; LOADING DRUG DOSE; MYASTHENIA GRAVIS; NEUROLOGY; NONHUMAN; POLYMYOSITIS; POLYRADICULONEUROPATHY; PRIORITY JOURNAL; REVIEW; TREATMENT DURATION;

ALZHEIMER DISEASE; AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM; GUILLAIN-BARRE SYNDROME; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MYOSITIS; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING;

EID: 72149128462     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2009.04025.x     Document Type: Review

References (69)

1. Imbach P, Barandun S, d'Apuzzo V et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981 1 : 1228 1231.
2. Vermeulen M, van der Meché FGA, Speelman JD et al. Plasma and gammaglobulin infusion in chronic inflammatory polyneuropathy. J Neurol Sci 1985 70 : 317 326.
3. Eftimov F, Winer JB, Vermeulen M et al. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy [update of Cochrane Database Syst Rev 2002;(2):CD001797 Cochrane Database Syst Rev 2009 1 : CD001797.
4. Hughes RA, Donofrio P, Bril V et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 2008 7 : 136 144.
5. Kleyweg RP, van der Meché FGA, Meulstee J. Treatment of Guillain-Barré Syndrome with high dose gammaglobulin. Neurology 1988 38 : 1639 1642.
6. van der Meché FG, Schmitz PI. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. N Engl J Med 1992 326 : 1123 1129.
7. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet 1997 349 : 225 230.
8. Hughes RC, Raphaël J-C, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev 2006 1 : CD002063.
9. van Schaik IN, Van den Berg LH, de Haan R. Intravenous immunoglobulin for multifocal motor neuropathy. Cochrane Database Syst Rev 2005 2 : CD004429.
10. Krendel DA, Costigan DA, Hopkins LC. Successful treatment of neuropathies in patients with diabetes mellitus. Arch Neurol 1995 52 : 1053 1061.
11. Levy Y, Uziel Y, Zandman G et al. Response of vasculitic peripheral neuropathy to intravenous immunoglobulin. Ann NY Acad Sci 2005 1051 : 779 786. (Pubitemid 41362802)
12. Kizawa M, Mori K, Iijima M et al. Intravenous immunoglobulin treatment in painful sensory neuropathy without sensory ataxia associated with Sjogren's syndrome. J Neurol Neurosurg Psychiatry 2006 77 : 967 969.
13. Elovaara I, Apostolski S, van Doorn P et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol 2008 15 : 893 908.
14. Feasby T, Banwell B, Benstead T et al. Guidelines on the use of intravenous immune globulin for neurologic conditions. Transfus Med Rev 2007 21 : S57 107.
15. Lin HH, Spies JM, Lu JL, Pollard JD Effective treatment of experimental autoimmune neuritis with human immunoglobulin. J Neurol Sci 2007 256 : 61 7.
16. Dalakas MC, Illa I, Dambrosia JM et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993 329 : 1993 2000.
17. Gajdos P, Chevret S, Toyka K. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev 2003 2 : CD002277.
18. Fazekas F, Lublin FD, Li D et al. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial. Neurology 2008 71 : 265 271.
19. Sorensen PS, Fazekas F, Lee M. Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple-sclerosis: a meta-analysis. Eur J Neurol 2002 9 : 557 563.
20. Counsell CE, McLeod M, Grant R. Reversal of subacute paraneoplastic cerebellar syndrome with intravenous immunoglobulin. Neurology 1994 44 : 1184 1185.
21. Uchuya M, Graus F, Vega F et al. Intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with antineuronal autoantibodies. J Neurol Neurosurg Psychiatry 1996 60 : 388 392.
22. Sahlas DJ, Miller SP, Guerin M et al. Treatment of acute disseminated encephalomyelitis with intravenous immunoglobulin. Neurology 2000 54 : 1370 1372.
23. Hart YM, Cortez M, Andermann F et al. Medical treatment of Rasmussen's syndrome (chronic encephalitis and epilepsy): effect of high-dose steroids or immunoglobulins in 19 patients. Neurology 1994 44 : 1030 1036.
24. Dauvilliers Y, Carlander B, Rivier F et al. Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset. Ann Neurol 2004 56 : 905 908.
25. Dodel RC, Du Y, Depboylu C et al. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2004 75 : 1472 1474.
26. Weksler ME, Relkin N, Turkenich R et al. Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp Gerontol 2002 37 : 943 948.
27. Du Y, Dodel R, Hampel H et al. Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology 2001 57 : 801 805.
28. Relkin N, Szabo P, Adamiak B et al. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging 2008 E-publication ahead of print).
29. Renaud S, Hays AP, Brannagan TH et al. Gene expression profiling in chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol 2005 159 : 203 214.
30. Sommer C, Koch S, Lammens M et al. Macrophage clustering as a diagnostic marker in sural nerve biopsies of patients with CIDP. Neurology 2005 65 : 1924 1929.
31. Kubori T, Mezaki T, Kaji T et al. The clinical usefulness of high dose intravenous immunoglobulin therapy for chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy. No To Shinkeil 1999 51 : 127 135 (In Japanese).
32. Mendell JR, Barohn RJ, Freimer ML et al. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuroapthy. Neurology 2001 56 : 445 449.
33. Latov N, Brill V, Katzberg H et al. Timing of clinical response to immune globulin intravenous, 10% caprylate/chromatography purified (IGIV-C) in chronic inflammatory demyelinating polyneuropathy (CIDP). Ann Neurol 2008 64 (Suppl. 12 S8 (Abstract M-18).
34. Hahn AF, Bolton CF, Zochode D, Feasby TE. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double blind, placebo-controlled, cross over study. Brain 1996 119 : 1067 1077.
35. Harbo T, Anderse H, Jakobsen J. Length dependent weakness and electrophysiologic signs of secondary axonal loss in chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 2008 38 : 1036 1045.
36. Rajabally YA, Seow H, Wilson P. Dose of intravenous immunoglobulins in chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst 2006 11 : 325 329.
37. Vucic S, Black K, Baldassari LE et al. Long-term effects of intravenous immunoglobulin in CIDP. Clin Neurophys 2007 118 : 1980 1984.
38. Hughes RA, Cornblath DR. Guillain-Barré syndrome. Lancet 2005 366 : 1653 1666.
39. van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol 2008 7 : 939 950.
40. The Italian Guillain-Barré Study Group. The prognosis and main prognostic indicators of Guillain-Barré syndrome. A multicentre prospective study of 297 patients. Brain 1996 119 : 2053 2061.
41. Hadden RD, Cornblath DR, Hughes RA et al. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Ann Neurol 1998 44 : 780 788.
42. McKhann GM, Cornblath DR, Ho T et al. Clinical and electrophysiological aspects of acute paralytic disease of children and young adults in northern China. Lancet 1991 338 : 593 597.
43. Bradshaw DY, Jones HR Jr. Guillain-Barré syndrome in children: clinical course, electrodiagnosis, and prognosis. Muscle Nerve 1992 15 : 500 506.
44. Hughes RA, Raphaël JC, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev 2006 1 : CD002063.
45. Gürses N, Uysal S, Cetinkaya F et al. Intravenous immunoglobulin treatment in children with Guillain-Barré syndrome. Scand J Infect Dis 1995 27 : 241 243.
46. Wang T, Feng A, Sun W, Wen Z. Intravenous immunoglobulin in children with Guillain-Barré syndrome. J Appl Clin Pediatr 2001 16 : 223 224.
47. Korinthenberg R, Schessl J, Kirschner J, Mönting JS. Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barré syndrome: a randomized trial. Pediatrics 2005 116 : 8 14.
48. Dalakas MC. Advances in the immunobiology and treatment of inflammatory myopathies. Curr Rheumatol Rep 2007 9 : 291 297.
49. Dalakas M. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA 2004 29 : 2367 2375.
50. Dalakas MC. Mechanisms of disease: signaling pathways and immunobiology of inflammatory myopathies. Nat Clin Pract Rheumatol 2006 2 : 219 227.
51. Dalakas MC. Clinical benefits and immunopathological correlates of intravenous immune globulin in the treatment of inflammatory myopathies. Clin Exp Immunol 1996 104 : 55 60.
52. Amemiya K, Semino-Mora C, Granger RP, Dalakas MC. Downregulation of TGF-beta1 mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin. Clin Immunol 2000 94 : 99 104.
53. Cherin P, Pelletier S, Teixeira A et al. Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum 2002 46 : 467 474.
54. Greenberg SA. Inclusion body myositis: review of recent literature. Curr Neurol Neurosci Rep 2009 9 : 83 9.
55. Dalakas MC, Sonies B, Dambrosia J et al. Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology 1997 48 : 712 716.
56. Dalakas MC, Koffman B, Fujii M et al. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 2001 56 : 323 327.
57. Raju R, Dalakas MC. Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes. Brain 2005 128 : 1887 1896.
58. Games D, Adams D, Alessandrini R et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 1995 373 : 523 527.
59. Schenk D, Barbour R, Dunn W et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999 400 : 173 177.
60. Janus C, Pearson J, McLaurin J et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000 408 : 979 982.
61. Morgan D, Diamond DM, Gottschall PE et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000 408 : 982 985.
62. Orgogozo JM, Gilman S, Dartigues JF et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003 61 : 46 54.
63. Gilman S, Koller M, Black RS et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005 64 : 1553 1562.
64. Bard F, Cannon C, Barbour R et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000 6 : 916 919.
65. Sohn JH, So JO, Kim H et al. Reduced serum level of antibodies against amyloid beta peptide is associated with aging in Tg2576 mice. Biochem Biophys Res Commun 2007 361 : 800 804.
66. Kellner A, Matschke J, Bernreuther C et al. Autoantibodies against β-amyloid are common in Alzheimer's disease and help control plaque burden. Ann Neurol 2009 65 : 24 31.
67. Dodel R, Hampel H, Depboylu C et al. Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease. Ann Neurol 2002 52 : 253 256.
68. Dodel R, Du Y, Depboylu C et al. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2004 75 : 1472 1474.
69. Tsakanikas D, Shah K, Flores C et al. Effects of uninterrupted intravenous immunoglobulin treatment of Alzheimer's disease for 9 months. International Conference on Alzheimer's Disease 2008 Abstract P4 351.